Zacks: Analysts Anticipate Cara Therapeutics Inc (NASDAQ:CARA) Will Post Quarterly Sales of $5.14 Million

Brokerages expect Cara Therapeutics Inc (NASDAQ:CARA) to report sales of $5.14 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Cara Therapeutics’ earnings, with estimates ranging from $5.00 million to $5.30 million. Cara Therapeutics posted sales of $2.87 million during the same quarter last year, which suggests a positive year-over-year growth rate of 79.1%. The company is scheduled to report its next earnings report after the market closes on Wednesday, August 7th.

On average, analysts expect that Cara Therapeutics will report full-year sales of $17.54 million for the current fiscal year, with estimates ranging from $4.38 million to $22.88 million. For the next financial year, analysts expect that the company will post sales of $21.10 million, with estimates ranging from $18.32 million to $25.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Cara Therapeutics.

Cara Therapeutics (NASDAQ:CARA) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.01). The company had revenue of $4.38 million during the quarter, compared to analysts’ expectations of $5.14 million. Cara Therapeutics had a negative return on equity of 67.30% and a negative net margin of 443.71%.

CARA has been the subject of a number of research analyst reports. Piper Jaffray Companies increased their price target on shares of Cara Therapeutics from $35.00 to $39.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th. BidaskClub lowered shares of Cara Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 30th. Laidlaw increased their price target on shares of Cara Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, May 29th. Zacks Investment Research raised shares of Cara Therapeutics from a “hold” rating to a “buy” rating and set a $27.00 price target for the company in a research report on Thursday. Finally, Needham & Company LLC increased their price target on shares of Cara Therapeutics from $28.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, May 29th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $26.94.

In related news, CFO Mani Mohindru sold 2,496 shares of the business’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $21.39, for a total value of $53,389.44. Following the completion of the transaction, the chief financial officer now directly owns 16,359 shares in the company, valued at approximately $349,919.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Derek T. Chalmers sold 5,528 shares of the business’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $21.42, for a total value of $118,409.76. Following the completion of the transaction, the chief executive officer now owns 963,996 shares of the company’s stock, valued at $20,648,794.32. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 88,348 shares of company stock worth $2,088,842. Insiders own 5.80% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. TCG Advisors LP acquired a new position in shares of Cara Therapeutics in the 1st quarter valued at approximately $30,000. Aperio Group LLC acquired a new position in shares of Cara Therapeutics in the 2nd quarter valued at approximately $88,000. Advisory Services Network LLC grew its position in shares of Cara Therapeutics by 39,086.4% in the 4th quarter. Advisory Services Network LLC now owns 8,621 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 8,599 shares during the period. BNP Paribas Arbitrage SA grew its position in shares of Cara Therapeutics by 67,680.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 6,778 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 6,768 shares during the period. Finally, Knott David M acquired a new position in shares of Cara Therapeutics in the 1st quarter valued at approximately $140,000. Institutional investors and hedge funds own 56.19% of the company’s stock.

Shares of NASDAQ CARA traded down $0.29 during mid-day trading on Monday, reaching $22.34. The company had a trading volume of 73,631 shares, compared to its average volume of 1,157,225. The business has a fifty day simple moving average of $22.53. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $865.76 million, a P/E ratio of -10.84 and a beta of 2.18. Cara Therapeutics has a 12-month low of $12.19 and a 12-month high of $27.55.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Further Reading: Cost of Goods Sold (COGS)

Get a free copy of the Zacks research report on Cara Therapeutics (CARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.